Supplementary Table S1. Abbreviations

Abbreviation	Full text
PLA	placebo/ no antibiotics
PRE1	2 g amoxicillin 1 hr pre-op
PRE2	1 g amoxicillin pre-op
PRE3	3 g amoxicillin 1 hr pre-op
POST1	2 g amoxicillin immediately post-op
POST2	Post-op amoxicillin with clavulanic acid 625 mg 3x daily for 5 days
POST3	500 mg q 8 h for 5 days post-op/postoperative amoxicillin, 1 g twice a day for 1 week after surgery
PREPO1	2 g amoxicillin pre-op and 500 mg amoxicillin post-op for 3 days
PREPO2	2 g amoxicillin 1 hr pre-op followed by 500 mg three times for 7 days
PREPO3	2 g amoxicillin 1 hr pre-op, 500 mg q 8 h for 5 days
PREPO4	2 g amoxicillin 1 hr pre-op followed by placebo post-op
PREPO5	2 g amoxicillin pre-op and 1 g amoxicillin postoperative, and 1 g twice a day for 2 days later
PREPO6	1 g amoxicillin pre-op and 500 mg amoxicillin post-op for 3 days
PREPO7	1 g amoxicillin 1 hr pre-op and 500 mg 4x daily for 2 days post-op
PREPO8	2 g amoxicillin 1 hr pre-op, followed by postoperative 1 g amoxicillin twice a day for 7 days
PREPO9	2 g amoxicillin 1 hr pre-op, followed by postoperative 500 mg thrice for 5 days
NMA	Network meta-analysis
SUCRA	Surface under cumulative ranking
RoB	Risk of bias
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
RR	Relative Risk
CI	Confidence Interval

Supplementary Table S2. Risk of bias assessment of included studies.

Author	Year	Random Sequence	Allocation Concealment	Blinding of Participants	Blinding of Outcome Assessment (Detection Bias)	Incomplete Outcome	Selective Reporting	Other Bias	Overall Bias
Momand et al.	2022	-	-	-	-	-	-	-	-
Tabrizi et al.	2022	-	-	?	-	-	-	-	?
Payer et al.	2020	-	-	-	-	+	+	-	+
Kashani et al.	2019	+	?	+	?	-	-	-	+
Andrade et al.	2017	-	?	?	?	-	?	?	?
Arduino et al.	2015	-	-	+	+	+	-	-	+
Nolan et al.	2014	-	-	-	-	+	-	-	+
Tan et al.	2014	-	-	-	-	-	-	-	-
El-Kholey et al.	2014	-	-	-	-	-	+	-	+
Karaky et al.	2011	+	+	+	-	+	?	+	+
Caiazzo et al.	2011	-	?	+	+	-	-	+	+
Esposito et al.	2010	-	-	-	-	-	-	-	-
Anitua et al.	2009	-	-	-	-	-	-	-	-
Abu-Ta'a et al.	2008	-	-	+	-	-	-	?	+
Esposito et al.	2008	-	-	-	-	-	-	+	+

Supplementary Table S3. Results of network meta-analysis from sensitivity analysis: implant failure (per patient data)

Treatment	Implant failure (patient)		
	Relative risk (95% CI)	P-value	SUCRA rank (score)
POST1	0.32 (0.01,7.86)	0.490	1 (73.8)
POST3	1.89 (0.07,49.63)	0.702	4 (41.1)
PRE1	0.63 (0.31,1.26)	0.192	3 (68.0)
PREPO1	0.31 (0.12,7.50)	0.472	2 (73.6)
PREPO2	4.96 (0.24,100.29)	0.296	6 (20.3)
PREPO3	3.15 (0.14,70.43)	0.469	5 (25.4)

Abbreviations: PLA = placebo/no antibiotics; PRE1 = 2 g amox 1 hr pre-op; POST1 = 2 g amox immediately post-op; POST3 = 500 mg q 8 h for 5 days post-op/postoperative amox 1 g twice a day for 1 week after surgery; PREPO1 = 2g amox pre-op and 500 mg amox post-op for 3 days; PREPO2 = 2 g amox 1 hr pre-op followed by 500 mg three times for 7 days; PREPO3 = 2 g amox 1 hr pre-op,500 mg q 8 h for 5 days

Supplementary Table S4. Results of network meta-analysis: prosthetic failure (patient)

Treatment	Prosthetic failure (Patient)		
	Relative risk (95% CI)	P-value	SUCRA rank (score)
PRE1	0.43 (0.16,1.11)	0.082	1 (89.7)
PREPO5	2.02 (0.08,48.38)	0.663	2 (25.4)

Abbreviations: PRE1 = 2 g amox 1 hr pre-op; PREPO5 = 2 g amox pre-op and 1 g amox postoperative, and 1 g twice a day for 2 days later

Supplementary Table S5. Results of network meta-analysis: postsurgical complications

Treatment	Postsurgical Complications		
	Relative risk (95% CI)	P-value	SUCRA rank (score)
POST1	2.27 (0.21,24.20)	0.495	10 (22.6)
POST2	0.61 (0.04,8.53)	0.714	4 (59.6)
POST3	0.75 (0.25,2.20)	0.604	5 (57.0)
PRE1	0.90 (0.52,1.57)	0.734	6 (49.2)
PRE3	0.20 (0.01,4.12)	0.302	2 (80.2)
PREPO1	1.89 (0.24,14.35)	0.537	8 (26.9)
PREPO3	1.14 (0.41,3.12)	0.797	7 (37.7)
PREPO5	0.56 (0.14,2.22)	0.417	3 (66.9)
PREPO7	0.25 (0.02,2.13)	0.206	1 (81.1)

PREPO9	1.90 (0.27,13.02)	0.511	9 (25.2)

Abbreviations: PRE1 = 2 g amox 1 hr pre-op; PRE3 = 3 g amox 1 hr pre-op; POST1 = 2 g amox immediately post-op; POST2 = post-op amox with clavulanic acid 625 mg 3x daily for 5 days; POST3 = 500 mg q 8 h for 5 days post-op/postoperative amox 1 g twice a day for 1 week after surgery; PREPO1 = 2 g amox pre-op and 500 mg amox post-op for 3 days; PREPO3 = 2 g amox 1 hr pre-op, 500 mg q 8 h for 5 days; PREPO5 = 2 g amox pre-op and 1 g amox postoperative, and 1 g twice a day for 2 days later; PREPO7 = 1 g amox 1 hr pre-op and 500 mg 4x daily for 2 days post-op; PREPO9 = 2 g amox 1 hr pre-op, followed by postoperative 500 mg thrice for 5 days

Supplementary Table S6. Results of network meta-analysis: adverse effect

Treatment	Adverse effect		
	Relative risk (95% CI)	P-value	SUCRA rank (score)
POST2	-0.18 (-4.46,4.09)	0.934	2 (64.7)
PRE1	0 (-1.74,1.75)	0.998	1 (66.5)
PREPO1	0 (-4.25,4.26)	0.999	3 (61.9)
PREPO2	2.31 (-1.05,5.68)	0.178	7 (21.1)
PREPO5	1.88 (-1.54,5.31)	0.282	6 (27.4)
PREPO7	0 (-3.89,3.89)	1.000	4 (59.8)
PREPO9	1.53 (-1.95,5.02)	0.389	5 (32.3)

Abbreviations: PRE1 = 2 g amox 1 hr pre-op; POST2 = post-op amox with clavulanic acid 625 mg 3x daily for 5 days; PREPO1 = 2 g amox pre-op and 500 mg amox post-op for 3 days; PREPO2 = 2 g amox 1 hr pre-op followed by 500 mg three times for 7 days; PREPO5 = 2 g amox pre-op and 1 g amox postoperative, and 1 g twice a day for 2 days later; PREPO7 = 1 g amox 1 hr pre-op and 500 mg 4x daily for 2 days post-op; PREPO9 = 2 g amox 1 hr pre-op, followed by postoperative 500 mg thrice for 5 days.

Supplementary Table S7. Network consistency for implant failure (patient), implant failure (implant), prosthetic failure (patient), postsurgical complications, and adverse effects

Category	Testing for inconsistency	
	Chi-square ($\chi 2$)	Prob > $\chi 2$
Implant failure (patient)	4.54	0.1033
Implant failure (implant)	1.53	0.4645
Prosthetic failure (patient)	1.00	0.3172
Postsurgical complications	0.51	0.9722
Adverse effects	1.56	0.2120

Supplementary Figure S1. Pairwise meta-analysis: implant failure (per patient data)

Study	exp(ES)	[95% conf. interval]		% weight
Group: POST.. PLA				
6	0.325	0.013	7.869	1.14
exp(theta)	0.325	0.013	7.869	
Group: PRE1.. P~2				
7	1.113	0.541	2.288	13.38
exp(theta)	1.113	0.541	2.288	
Group: PRE1.. P~3				
2	0.333	0.014	8.118	1.13
exp(theta)	0.333	0.014	8.118	
Group: PRE1.. PLA				
3	0.381	0.195	0.744	14.55
5	0.032	0.002	0.564	1.40
9	0.420	0.150	1.175	8.35
10	1.019	0.149	6.968	2.94
11	0.250	0.054	1.159	4.39
13	0.846	0.289	2.481	7.81
exp(theta)	0.429	0.251	0.733	
Group: PRE3.. P~1				
5	2.929	0.059	144.156	0.77
exp(theta)	2.929	0.059	144.156	
Group: PRE3.. PLA				
5	0.094	0.005	1.625	1.41
exp(theta)	0.094	0.005	1.625	
Group: PREP.. P~1				
6	0.954	0.019	47.527	0.76
exp(theta)	0.954	0.019	47.527	
Group: PREP.. PLA				
6	0.310	0.013	7.510	1.14
12	3.051	0.322	28.913	2.20
exp(theta)	1.301	0.149	11.352	
Group: PREP.. P~1				
15	7.875	0.423	146.697	1.34
exp(theta)	7.875	0.423	146.697	
Group: PREP.. P~3				
2	1.667	0.223	12.459	2.71
exp(theta)	1.667	0.223	12.459	
Group: PREP.. P~1				
2	5.000	0.242	103.277	1.25
exp(theta)	5.000	0.242	103.277	
Group: PREP.. P~1				
4	0.938	0.277	3.181	6.41
exp(theta)	0.938	0.277	3.181	
Group: PREP.. PLA				
14	0.143	0.008	2.679	1.33
exp(theta)	0.143	0.008	2.679	
Group: PREP.. P~2				
7	0.943	0.448	1.982	12.90
exp(theta)	0.943	0.448	1.982	
Group: PREP.. P~1				
7	0.847	0.399	1.800	12.69
exp(theta)	0.847	0.399	1.800	
Overall				
exp(theta)	0.700	0.495	0.990	

Supplementary Figure S2. Sensitivity analysis network plot : implant failure (per patient data)


Abbreviations: PLA = placebo/no antibiotics; PRE1 = 2 g amox 1 hr pre-op; POST1 = 2 g amox immediately post-op; POST3 = 500 mg q 8 h for 5 days post-op/postoperative amox 1 g twice a day for 1 week after surgery; PREPO1 = 2 g amox pre-op and 500 mg amox post-op for 3 days; PREPO2 = 2 g amox 1 hr pre-op followed by 500 mg three times for 7 days; PREPO3 = 2 g amox 1 hr pre-op, 500 mg q 8 h for 5 days

Supplementary Figure S3. Sensitivity analysis network plot : implant failure (per implant data)

Study	exp(ES)	[95% conf. interval]		% weight
Group: POST.. PLA				
8	0.122	0.006	2.465	1.31
exp(theta)	0.122	0.006	2.465	
Group: PRE1.. P~2				
7	1.289	0.636	2.612	13.66
exp(theta)	1.289	0.636	2.612	
Group: PRE1.. P~3				
2	0.333	0.014	8.118	1.17
8	1.361	0.028	66.990	0.79
exp(theta)	0.587	0.050	6.931	
Group: PRE1.. PLA				
3	0.300	0.156	0.575	14.90
8	0.167	0.008	3.339	1.32
9	0.532	0.214	1.322	10.01
10	1.019	0.149	6.968	3.01
13	1.029	0.390	2.715	9.18
exp(theta)	0.506	0.284	0.901	
Group: PREP.. PLA				
12	3.051	0.322	28.913	2.26
exp(theta)	3.051	0.322	28.913	
Group: PREP.. P~3				
2	1.667	0.223	12.459	2.77
exp(theta)	1.667	0.223	12.459	
Group: PREP.. P~1				
2	5.000	0.242	103.277	1.29
exp(theta)	5.000	0.242	103.277	
Group: PREP.. P~1				
4	1.539	0.510	4.648	7.59
exp(theta)	1.539	0.510	4.648	
Group: PREP.. PLA				
14	0.085	0.005	1.513	1.42
exp(theta)	0.085	0.005	1.513	
Group: PREP.. P~3				
8	1.324	0.027	65.204	0.79
exp(theta)	1.324	0.027	65.204	
Group: PREP.. P~1				
8	0.973	0.020	47.731	0.79
exp(theta)	0.973	0.020	47.731	
Group: PREP.. PLA				
8	0.162	0.008	3.250	1.32
exp(theta)	0.162	0.008	3.250	
Group: PREP.. P~2				
7	0.945	0.458	1.949	13.30
exp(theta)	0.945	0.458	1.949	
Group: PREP.. P~1				
7	0.733	0.352	1.526	13.11
exp(theta)	0.733	0.352	1.526	
Overall				
exp(theta)	0.757	0.533	1.076	

Supplementary Figure S4. Network plot: prosthetic failure (patient)

Supplementary Figure S5. SUCRA ranking curve for prosthetic failure (patient)

Abbreviations: PLA = placebo/no antibiotics; PRE1 = 2 g amox 1 hr pre-op; PREPO5 = 2 g amox pre-op and 1 g amox postoperative, and 1 g twice a day for 2 days later.

Supplementary Figure S6. League table for prosthetic failure (patient)

PRE1		
0.21 (0.01,4.41)	PREPO5	
0.43 (0.17,1.11)	2.02 (0.08,48.38)	PLA

Abbreviations: PLA = placebo/no antibiotics; PRE1 = 2 g amox 1 hr pre-op; PREPO5 = 2 g amox pre-op and 1 g amox postoperative, and 1 g twice a day for 2 days later

Supplementary Figure S7. Pairwise meta-analysis for prosthetic failure (patient)

Study	exp(ES)	[95% conf. interval]		% weight
Group: POST.. PLA				
8	0.122	0.006	2.465	1.31
exp(theta)	0.122	0.006	2.465	
Group: PRE1.. P~2				
7	1.289	0.636	2.612	13.66
exp(theta)	1.289	0.636	2.612	
Group: PRE1.. P~3				
2	0.333	0.014	8.118	1.17
8	1.361	0.028	66.990	0.79
exp(theta)	0.587	0.050	6.931	
Group: PRE1.. PLA				
3	0.300	0.156	0.575	14.90
8	0.167	0.008	3.339	1.32
9	0.532	0.214	1.322	10.01
10	1.019	0.149	6.968	3.01
13	1.029	0.390	2.715	9.18
exp(theta)	0.506	0.284	0.901	
Group: PREP.. PLA				
12	3.051	0.322	28.913	2.26
exp(theta)	3.051	0.322	28.913	
Group: PREP.. P~3				
2	1.667	0.223	12.459	2.77
exp(theta)	1.667	0.223	12.459	
Group: PREP.. P~1				
2	5.000	0.242	103.277	1.29
exp(theta)	5.000	0.242	103.277	
Group: PREP.. P~1				
4	1.539	0.510	4.648	7.59
exp(theta)	1.539	0.510	4.648	
Group: PREP.. PLA				
14	0.085	0.005	1.513	1.42
exp(theta)	0.085	0.005	1.513	
Group: PREP.. P~3				
8	1.324	0.027	65.204	0.79
exp(theta)	1.324	0.027	65.204	
Group: PREP.. P~1				
8	0.973	0.020	47.731	0.79
exp(theta)	0.973	0.020	47.731	
Group: PREP.. PLA				
8	0.162	0.008	3.250	1.32
exp(theta)	0.162	0.008	3.250	
Group: PREP.. P~2				
7	0.945	0.458	1.949	13.30
exp(theta)	0.945	0.458	1.949	
Group: PREP.. P~1				
7	0.733	0.352	1.526	13.11
exp(theta)	0.733	0.352	1.526	
Overall				
exp(theta)	0.757	0.533	1.076	

Supplementary Figure S8. Network plot: postsurgical complications

Abbreviations: PLA = placebo/no antibiotics; PRE1 = 2 g amox 1 hr pre-op; PRE3 = 3 g amox 1 hr pre-op; POST1 = 2 g amox immediately post-op; POST2 = post-op amox with clavulanic acid 625 mg 3x daily for 5 days; POST3 = 500 mg q 8 h for 5 days post-op/postoperative amox 1 g twice a day for 1 week after surgery; PREPO1 = 2 g amox pre-op and 500 mg amox post-op for 3 days; PREPO3 = 2 g amox 1 hr pre-op, 500 m g q 8 h for 5 days; PREPO5 = 2 g amox pre-op and 1 g amox postoperative, and 1 g twice a day for 2 days later; PREPO7 = 1 g amox 1 hr pre-op and 500 mg 4x daily for 2 days post-op; PREPO9 = 2 g amox 1 hr pre-op, followed by postoperative 500 mg thrice for 5 days

Supplementary Figure S9. SUCRA ranking curve for postsurgical complications

Graphs by Treatment

Abbreviations: PLA = placebo/no antibiotics; PRE1 = 2 g amox 1 hr pre-op; PRE3 = 3 g amox 1 hr pre-op; POST1 = 2 g amox immediately post-op; POST2=post-op amox with clavulanic acid 625 mg 3x daily for 5 days; POST3 = 500 mg q 8 h for 5 days post-op/postoperative amox 1 g twice a day for 1 week after surgery; PREPO1 = 2 g amox pre-op and 500 mg amox post-op for 3 days; PREPO3 = 2 g amox 1 hr pre-op, 500 mg q 8 h for 5 days; PREPO5 = 2 g amox pre-op and 1 g amox postoperative, and 1 g twice a day for 2 days later; PREPO7 = 1 g amox 1 hr pre-op and 500 mg 4x daily for 2 days post-op; PREPO9 = 2 g amox 1 hr pre-op, followed by postoperative 500 mg thrice for 5 days

# Supplementary Figure S10. League table for postsurgical complications

POST1										
3.73 (0.12,115.22)	POST2									
3.03 (0.25,36.64)	0.81 (0.05,12.23)	POST3								
2.51 (0.24,26.25)	0.67 (0.05,8.89)	0.83 (0.33,2.09)	PRE1							
11.00 (0.24,497.79)	2.95 (0.05,159.12)	3.63 (0.15,87.22)	4.39 (0.21,91.92)	PRE3						
1.20 (0.14,10.41)	0.32 (0.01,7.58)	0.40 (0.05,3.39)	0.48 (0.07,3.54)	0.11 (0.00,4.06)	PREPO1					
2.00 (0.17,23.89)	0.54 (0.04,7.99)	0.66 (0.27,1.63)	0.80 (0.34,1.85)	0.18 (0.01,4.26)	1.66 (0.19,14.14)	PREPO3				
4.01 (0.28,57.28)	1.07 (0.06,18.92)	1.32 (0.28,6.25)	1.60 (0.46,5.57)	0.36 (0.01,9.77)	3.33 (0.32,35.11)	2.01 (0.45,9.05)	PREPO5			
9.11 (0.37,221.98)	2.44 (0.08,73.28)	3.01 (0.27,33.19)	3.64 (0.40,33.37)	0.83 (0.02,32.93)	7.57 (0.40,144.99)	4.57 (0.43,48.91)	2.27 (0.18,28.93)	PREPO7		
1.20 (0.07,21.58)	0.32 (0.03,2.95)	0.39 (0.05,2.95)	0.48 (0.08,3.02)	0.11 (0.00,3.81)	0.99 (0.08,12.69)	0.60 (0.08,4.46)	0.30 (0.03,2.77)	0.13 (0.01,2.34)	PREPO9	
2.28 (0.21,24.21)	0.61 (0.04,8.54)	0.75 (0.26,2.20)	0.91 (0.52,1.58)	0.21 (0.01,4.13)	1.89 (0.25,14.36)	1.14 (0.42,3.12)	0.57 (0.15,2.22)	0.25 (0.03,2.14)	1.91 (0.28,13.02)	PLA

Abbreviations: PLA = placebo/no antibiotics; PRE1 = 2 g amox 1 hr pre-op; PRE3 = 3 g amox 1 hr pre-op; POST1 = 2 g amox immediately post-op; POST2 = post-op amox with clavulanic acid 625 mg 3x daily for 5 days; POST3 = 500 mg q 8 h for 5 days post-op/postoperative amox 1 g twice a day for 1 week after surgery; PREPO1 = 2 g amox pre-op and 500 mg amox post-op for 3 days; PREPO3 = 2 g amox 1 hr pre-op, 500 mg q 8 h for 5 days; PREPO5 = 2 g amox pre-op and 1 g amox postoperative, and 1 g twice a day for 2 days later; PREPO7 = 1 g amox 1 hr pre-op and 500 mg 4x daily for 2 days post-op; PREPO9 = 2 g amox 1 hr pre-op, followed by postoperative 500 mg thrice for 5 days

Supplementary Figure S11. Pairwise meta-analysis for postsurgical complications

Study	exp(ES)	[95% conf. interval]		% weight
Group: POST.. PLA				
6	2.928	0.121	70.821	1.05
exp(theta)	2.928	0.121	70.821	
Group: PRE1.. P~1				
6	0.337	0.014	8.162	1.05
exp(theta)	0.337	0.014	8.162	
Group: PRE1.. P~2				
7	1.205	0.077	18.940	1.40
exp(theta)	1.205	0.077	18.940	
Group: PRE1.. P~3				
2	1.286	0.492	3.363	11.52
8	1.000	0.021	48.524	0.71
exp(theta)	1.267	0.498	3.222	
Group: PRE1.. PLA				
6	0.988	0.020	49.186	0.70
9	0.733	0.300	1.792	13.32
10	1.019	0.351	2.956	9.39
11	1.750	0.523	5.860	7.29
13	0.395	0.077	2.016	4.01
exp(theta)	0.901	0.518	1.568	
Group: PRE3.. PLA				
5	0.207	0.010	4.126	1.19
exp(theta)	0.207	0.010	4.126	
Group: PREP.. P~1				
6	0.954	0.101	8.989	2.12
exp(theta)	0.954	0.101	8.989	
Group: PREP.. P~3				
8	1.000	0.021	48.524	0.71
exp(theta)	1.000	0.021	48.524	
Group: PREP.. P~1				
6	2.828	0.117	68.428	1.05
8	1.000	0.021	48.524	0.71
exp(theta)	1.861	0.159	21.845	
Group: PREP.. PLA				
6	2.793	0.115	67.587	1.05
exp(theta)	2.793	0.115	67.587	
Group: PREP.. P~3				
2	1.571	0.626	3.944	12.57
exp(theta)	1.571	0.626	3.944	
Group: PREP.. P~1				
2	1.222	0.522	2.863	14.69
exp(theta)	1.222	0.522	2.863	
Group: PREP.. P~1				
4	0.625	0.180	2.176	6.84
exp(theta)	0.625	0.180	2.176	
Group: PREP.. PLA				
14	0.250	0.029	2.140	2.31
exp(theta)	0.250	0.029	2.140	
Group: PREP.. P~2				
7	3.342	0.355	31.475	2.12
exp(theta)	3.342	0.355	31.475	
Group: PREP.. P~3				
8	1.000	0.021	48.524	0.71
exp(theta)	1.000	0.021	48.524	
Group: PREP.. P~1				
7	2.772	0.295	26.058	2.12
8	1.000	0.021	48.524	0.71
exp(theta)	2.149	0.309	14.961	
Group: PREP.. PR~1				
8	1.000	0.021	48.524	0.71
exp(theta)	1.000	0.021	48.524	
Overall				
exp(theta)	1.069	0.771	1.481	

Supplementary Figure S12. Network plot: adverse effect

Abbreviations: PLA = placebo/no antibiotics; PRE1 = 2 g amox 1 hr pre-op; POST2 = post-op amox with clavulanic acid 625 mg 3x daily for 5 days; PREPO1 = 2 g amox pre-op and 500 mg amox post-op for 3 days; PREPO2 = 2 g amox 1 hr pre-op followed by 500 mg three times for 7 days; PREPO5 = 2 g amox pre-op and 1 g amox postoperative, and 1 g twice a day for 2 days later; PREPO7 = 1 g amox 1 hr pre-op and 500 mg 4x daily for 2 days post-op; PREPO9 = 2 g amox 1 hr pre-op, followed by postoperative 500 mg thrice for 5 days

Supplementary Figure S13. SUCRA ranking curve for adverse effect

Graphs by Treatment

Abbreviations: PLA = placebo/no antibiotics; PRE1 = 2 g amox 1 hr pre-op; POST2 = post-op amox with clavulanic acid 625 mg 3x daily for 5 days; PREPO1 = 2 g amox pre-op and 500 mg amox post-op for 3 days; PREPO2 = 2 g amox 1 hr pre-op followed by 500 mg three times for 7 days; PREPO5 = 2 g amox pre-op and 1 g amox postoperative, and 1 g twice a day for 2 days later; PREPO7 = 1 g amox 1 hr pre-op and 500 mg 4x daily for 2 days post-op; PREPO9 = 2 g amox 1 hr pre-op, followed by postoperative 500 mg thrice for 5 days

Supplementary Figure S14. League table for adverse effect

POST2							
0.83 (0.02,41.40)	PRE1						
0.83 (0.00,205.13)	1.00 (0.02,48.52)	PREPO1					
0.08 (0.00,10.55)	0.10 (0.01,1.76)	0.10 (0.00,12.43)	PREPO2				
0.13 (0.00,17.00)	0.15 (0.01,2.93)	0.15 (0.00,20.03)	1.54 (0.02,95.69)	PREPO5			
0.83 (0.00,272.19)	1.00 (0.01,71.73)	1.00 (0.00,321.74)	10.15 (0.06,1753.57)	6.58 (0.04,1185.73)	PREPO7		
0.18 (0.01,3.69)	0.22 (0.01,4.43)	0.22 (0.00,29.57)	2.19 (0.03,142.31)	1.42 (0.02,97.14)	0.22 (0.00,40.29)	PREPO9	
0.83 (0.01,60.29)	1.00 (0.17,5.76)	1.00 (0.01,70.83)	10.15 (0.35,295.47)	6.58 (0.21,204.13)	1.00 (0.02,49.20)	4.64 (0.14,151.95)	PLA

Abbreviations : PLA = placebo/no antibiotics; PRE1 = 2 g amox 1 hr pre-op; POST2 = post-op amox with clavulanic acid 625 mg 3x daily for 5 days; PREPO1 = 2 g amox pre-op and 500 mg amox post-op for 3 days; PREPO2 = 2 g amox 1 hr pre-op followed by 500 mg three times for 7 days; PREPO5 = 2 g amox pre-op and 1 g amox postoperative, and 1 g twice a day for 2 days later; PREPO7 = 1 g amox 1 hr pre-op and 500 mg 4x daily for 2 days post-op; PREPO9 = 2 g amox 1 hr pre-op, followed by postoperative 500 mg thrice for 5 days

# Supplementary Figure S15. Pairwise meta-analysis for adverse effects

Study	exp(ES)	[95% conf. interval]		% weight
Group: PRE1.. P~2				
7	1.203	0.024	59.881	6.69
exp(theta)	1.203	0.024	59.881	
Group: PRE1.. PLA				
9	1.008	0.020	50.600	6.66
10	1.019	0.021	50.413	6.71
11	1.000	0.063	15.848	13.38
13	0.987	0.020	49.559	6.66
exp(theta)	1.003	0.175	5.762	
Group: PREP.. P~1				
8	1.000	0.021	48.524	6.78
exp(theta)	1.000	0.021	48.524	
Group: PREP.. P~1				
15	10.125	0.567	180.853	12.29
exp(theta)	10.125	0.567	180.853	
Group: PREP.. P~1				
4	6.567	0.342	126.188	11.69
exp(theta)	6.567	0.342	126.188	
Group: PREP.. PLA				
14	1.000	0.020	49.203	6.73
exp(theta)	1.000	0.020	49.203	
Group: PREP.. P~2				
7	5.562	0.271	114.132	11.19
exp(theta)	5.562	0.271	114.132	
Group: PREP.. P~1				
7	4.625	0.226	94.759	11.20
exp(theta)	4.625	0.226	94.759	
Overall				
exp(theta)	2.415	0.879	6.635	

Heterogeneity summary

Group	df	Q	P > Q	tau2	% I2	H2
PRE1 vs. PO~2	0	0.00	.	0.000	.	.
PRE1 vs. PLA	3	0.00	1.000	0.000	0.00	1.00
PREPO1 .. P~1	0	0.00	.	0.000	.	.
PREPO2 .. P~1	0	0.00	.	0.000	.	.
PREPO5 .. P~1	0	0.00	.	0.000	.	.
PREPO7 vs. PLA	0	0.00	.	0.000	.	.
PREPO9 .. P~2	0	0.00	.	0.000	.	.
PREPO9 .. P~1	0	0.00	.	0.000	.	.
Overall	10	3.35	0.972	0.000	0.00	1.00

Test of group differences: Q_b = chi2(7) = 3.35   Prob > Q_b = 0.851

Supplementary Figure S16. Comparison-adjusted funnel plot for implant failure (patient)


Supplementary Figure S17. Comparison-adjusted funnel plot for implant failure (per implant data)

Supplementary Figure S18. Comparison-adjusted funnel plot for prosthetic failure

Supplementary Figure S19. Comparison-adjusted funnel plot for postsurgical complications

Supplementary Figure S20. Comparison-adjusted funnel plot for adverse effects